Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and XXXX .

@entity2304 @entity5 @entity19 @entity1961 @entity1611
Dendritic cell (DC)-based vaccination is a promising strategy for @entity5 immunotherapy. However, clinical trials have indicated that immunosuppressive microenvironments induced by @entity5 profoundly suppress antitumor immunity and inhibit vaccine efficacy, resulting in @entity5 burdens. To overcome these obstacles and enhance the efficiency of DC vaccination, we generated interleukin (IL)-12- and granulocyte-macrophage colony-stimulating factor ( @entity2304 )-coexpressing oncolytic adenovirus (Ad-/\B7/IL12/ @entity2304 ) as suitable therapeutic adjuvant to eliminate immune suppression and promote DC function. By treating @entity5 with Ad-/\B7/IL12/ @entity2304 prior to DC vaccination, DCs elicited greater antitumor effects than in response to either treatment alone. DC migration to draining lymph nodes (DLNs) dramatically increased in @entity19 treated with the combination therapy. This result was associated with upregulation of CC-chemokine ligand 21 (CCL21(+)) lymphatics in @entity5 treated with Ad-/\B7/IL12/ @entity2304 . Moreover, the proportion of @entity1961 (+)CD25(+) T-cells and @entity1611 ( @entity1611 ) expression was decreased in @entity19 treated with the combination therapy. Furthermore, combination therapy using immature DCs also showed effective antitumor effects when combined with Ad-/\B7/IL12/ @entity2304 . The combination therapy had a remarkable therapeutic efficacy on large @entity5 . Taken together, oncolytic adenovirus coexpressing IL-12 and @entity2304 in combination with DC vaccination has synergistic antitumor effects and can act as a potent adjuvant for promoting and optimizing DC vaccination.
